Galderma research finds 56% misread menopause-related skin changes; stock pre-market at EUR 180.25
Published on 10/13/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Galderma announced menopause-related skin research on October 13, 2026.
- The survey found 56% of women initially attributed related skin changes to aging.
- Galderma stock was at EUR 180.25 in pre-market trading at Lang & Schwarz.
On October 13, 2026, Galderma announced global research showing that 56% of surveyed women initially attributed menopause-related skin changes to general aging. At 8:17 a.m. CEST, Galderma stock was at EUR 180.25 in pre-market trading at Lang & Schwarz on October 13, 2026.
Research highlights awareness gap
The company said 29% of women initially recognized the connection between the changes and menopause, while 70% had bought products intended for signs of aging because they believed those products would address changes experienced during perimenopause or menopause. The survey covered 5,090 women in the United Kingdom, United States, Brazil and China, with data collected from August 25 through September 1, 2026. The release said more than 80% agreed that better understanding the difference between general aging and menopause-related skin changes would help them make more informed skincare decisions.
What matters today
World Menopause Day is scheduled for October 18, 2026. Galderma’s research cites 70% as the share of women who bought aging-focused products for menopause-related skin changes. The study included 5,090 women across four countries.
Pre-market indication
The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Galderma stock.
Market context: Market report SMI.
